1-6 of 6
Christopher Daly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B129: A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

Yan Yang, Naga Suhasini Avvaru, Zaoli Jiang, Nina Liu, Michael Rosconi, Bojie Zhang, Yinyin Li, Erica Ullman, John Chia-Yang Lin, Yang Shen, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B129.
https://doi.org/10.1158/1535-7163.TARG-23-B129
Published: 01 December 2023
View article titled, Abstract B129: A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models
Journal Articles

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Andres E. Perez Bay, Devon Faulkner, John O. DaSilva, Tara M. Young, Katie Yang, Jason T. Giurleo, Dangshe Ma, Frank J. Delfino, William C. Olson, Gavin Thurston, Christopher Daly, Julian Andreev
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (3): 357–370.
https://doi.org/10.1158/1535-7163.MCT-22-0414
Published: 02 March 2023
View article titled, A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Open the PDF for A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes in another window
Includes: Supplementary data
Journal Articles

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Retter, Rabih Slim, Tara M. Young, William C. Olson, Gavin Thurston, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1966–1976.
https://doi.org/10.1158/1535-7163.MCT-21-0009
Published: 01 October 2021
View article titled, A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
Open the PDF for A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade in another window
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data
Journal Articles

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Li Zhang, Carla Castanaro, Bo Luan, Katie Yang, Liangfen Fan, Jeanette L. Fairhurst, Ashique Rafique, Terra B. Potocky, Jing Shan, Frank J. Delfino, Ergang Shi, Tammy Huang, Joel H. Martin, Gang Chen, Douglas MacDonald, John S. Rudge, Gavin Thurston, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1345–1355.
https://doi.org/10.1158/1535-7163.MCT-13-1033
Published: 05 May 2014
View article titled, ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Open the PDF for ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models in another window
Includes: Supplementary data
Journal Articles

Abstract A10: Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts.

Alshad S. Lalani, Carla Castanaro, Alastair H. Kyle, Andrew I. Minchinton, Gavin Thurston, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A10.
https://doi.org/10.1158/1535-7163.TARG-11-A10
Published: 12 November 2011
View article titled, Abstract A10: Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts.